Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer

Liu,Rong; Martin,Tracey A.; Jordan,Nicola J.; Ruge,Fiona; Ye,Lin; Jiang,Wen G.

doi:10.3892/ijo.2016.3462

Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer

Authors:
- Rong Liu
- Tracey A. Martin
- Nicola J. Jordan
- Fiona Ruge
- Lin Ye
- Wen G. Jiang
View Affiliations

Affiliations: Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK
Published online on: March 29, 2016 https://doi.org/10.3892/ijo.2016.3462
Pages: 2488-2496

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial protein lost in neoplasm-α (EPLIN-α) is a cytoskeletal protein whose expression is often lost or is aberrant in cancerous cells and tissues and whose loss is believed to be involved in aggressive phenotypes. This study examined this molecule in human epithelial ovarian tissues and investigated the cellular impact of EPLIN-α on ovarian cancer cells (EOC), SKOV3 and COV504. The expression of EPLIN-α in human ovarian tissues and EOC was assessed at both the mRNA and protein levels using reverse transcription-PCR (RT-PCR) and immunohistochemistry, respectively. In vitro assays for cellular matrix adhesion and migration (confirmed by an electrical cell substrate impedance sensing (ECIS) based method), invasion and cell growth were employed in order to assess the biological influence of EPLIN-α expression on EOC cells. Immunohistochemical analysis of ovarian cancer samples demonstrated that only a small number expressed EPLIN-α protein. Downregulation of EPLIN-α protein in EOC cell lines increased the growth, invasion, adhesion and migration in vitro. This EPLIN-α downregulation may have a prognostic value. From these data, we conclude that downregulation of EPLIN-α may be associated with poorer patient prognosis, and that this molecule appears to play a tumour suppressor role by inhibition of EOC growth and migration.

View Figures

View References

1	Chang DD, Park NH, Denny CT, Nelson SF and Pe M: Characterization of transformation related genes in oral cancer cells. Oncogene. 16:1921–1930. 1998. View Article : Google Scholar : PubMed/NCBI
2	Song Y, Maul RS, Gerbin CS and Chang DD: Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol Biol Cell. 13:1408–1416. 2002. View Article : Google Scholar : PubMed/NCBI
3	Maul RS, Song Y, Amann KJ, Gerbin SC, Pollard TD and Chang DD: EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol. 160:399–407. 2003. View Article : Google Scholar : PubMed/NCBI
4	Abe K and Takeichi M: EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci USA. 105:13–19. 2008. View Article : Google Scholar
5	Maul RS and Chang DD: EPLIN, epithelial protein lost in neoplasm. Oncogene. 18:7838–7841. 1999. View Article : Google Scholar
6	Chen S, Maul RS, Kim HR and Chang DD: Characterization of the human EPLIN (epithelial protein lost in neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene. 248:69–76. 2000. View Article : Google Scholar : PubMed/NCBI
7	Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer. 7:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sanders AJ, Martin TA, Ye L, Mason MD and Jiang WG: EPLIN is a negative regulator of prostate cancer growth and invasion. J Urol. 186:295–301. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, et al: EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene. 30:4941–4952. 2011. View Article : Google Scholar : PubMed/NCBI
10	Han MY, Kosako H, Watanabe T and Hattori S: Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol Cell Biol. 27:8190–8204. 2007. View Article : Google Scholar : PubMed/NCBI
11	Seong BKA, Lau J, Adderley T, Kee L, Chaukos D, Pienkowska M, Malkin D, Thorner P and Irwin MS: SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. Oncogene. 34:3582–3592. 2015. View Article : Google Scholar
12	Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Fürst K, Kowtharapu BS, Engelmann D, Petigk J, Egberts F, et al: DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell. 24:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
13	Jiang WG, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE and Fodstad O: Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status. Int J Cancer. 117:730–737. 2005. View Article : Google Scholar : PubMed/NCBI
14	Jiang WG, Davies G and Fodstad O: Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. Biochem Biophys Res Commun. 330:253–262. 2005. View Article : Google Scholar : PubMed/NCBI
15	Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD and Fodstad O: Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med. 18:981–986. 2006.PubMed/NCBI
16	Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD and Mansel RE: Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med. 17:583–590. 2006.PubMed/NCBI
17	Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K and Mansel RE: Targeting matrilysin and its impact on tumor growth in vivo: The potential implications in breast cancer therapy. Clin Cancer Res. 11:6012–6019. 2005. View Article : Google Scholar : PubMed/NCBI
18	Jiang WG, Hiscox S, Singhrao SK, Nakamura T, Puntis MC and Hallett MB: Inhibition of HGF/SF-induced membrane ruffling and cell motility by transient elevation of cytosolic free Ca²⁺. Exp Cell Res. 220:424–433. 1995. View Article : Google Scholar : PubMed/NCBI
19	Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Scott C and Puntis MCA: Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid. Br J Cancer. 71:744–752. 1995. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Sanders AJ, Zhang L and Jiang WG: EPLIN-Alpha expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome. Anticancer Res. 32:1283–1289. 2012.PubMed/NCBI
21	Sanders AJ, Ye L, Mason MD and Jiang WG: The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis. 13:317–326. 2010. View Article : Google Scholar : PubMed/NCBI